XBiotech Inc. — Q3 2017 Form 10-Q
Business context and reporting period
XBiotech is a pre-revenue biopharmaceutical company developing naturally occurring “True Human” monoclonal antibodies. This unaudited filing covers the quarter and nine months ended September 30, 2017; balance-sheet comparisons are against December 31, 2016.
Financial performance and position
- Revenue: None in Q3 or the first nine months of 2017 or 2016.
- Net loss: Q3 loss was $6.2 million, versus $12.5 million in Q3 2016. Nine-month loss was $25.9 million, versus $36.4 million. Basic and diluted loss per share was $0.18 and $0.72, respectively, compared with $0.38 and $1.12 in the comparable periods.
- Expenses: Q3 operating expenses were $6.6 million, down 47% year over year; nine-month expenses were $26.6 million, down 27%. R&D expense was $4.9 million for Q3 and $20.5 million for nine months; G&A was $1.7 million and $6.0 million, respectively.
- Cash flow: Cash used in operations was $26.8 million for the first nine months, compared with $33.2 million in 2016. Investing used $1.2 million, versus $11.9 million; financing provided $33.3 million, chiefly from equity issuance. Cash increased by $4.7 million to $39.0 million.
- Liquidity and debt: Current assets were $40.3 million and current liabilities $3.5 million at September 30. Total liabilities were $3.5 million; no borrowings are reported. Management said cash should fund operating and capital needs through 2018, subject to assumptions that may prove incorrect.
- Other balance-sheet items: Total assets were $70.7 million, including $30.4 million in property and equipment. Accumulated deficit was $209.3 million. No product margins are reported because the company has no revenue.
Material changes and operating developments
- Lower R&D costs reflected reduced manufacturing and laboratory spending, completion of a global trial, and a smaller R&D workforce; total employee count fell to 56 from 106 a year earlier.
- The EMA’s CHMP maintained its negative opinion on the European marketing application for Xilonix on September 14, 2017. XBiotech had also discontinued its FDA Phase III global trial in June; data analysis was ongoing, and the company said no further EMA procedure was available for the current application.
- Cash was supported by a March 2017 equity sale of 2.4 million shares for approximately $31.6 million in net proceeds, along with other share issuance and option exercises.
Outlook, risks, contingencies and unusual items
- Management expects substantial operating losses to continue and says profitability depends on successful development, regulatory approval and commercialization, none of which is assured. It expects clinical costs could decline after completed studies but could rise if advanced studies proceed.
- The company reported positive top-line results from Phase II studies in hidradenitis suppurativa and Staphylococcus aureus bloodstream infections, and was seeking FDA guidance on protocols for advanced studies. It was also considering oncology studies and potential research or clinical partnerships.
- Two securities class-action matters concern alleged disclosures about the Xilonix European Phase III trial. The re-filed Texas matter was stayed in October 2017 pending a U.S. Supreme Court case; the company said it could not estimate the outcome or financial impact. A separate suit filed October 26, 2017 alleged misleading statements about Xilonix; the filing said there was then no material financial impact and future impact could not be measured.
- After a director resigned on November 8, NASDAQ notified the company of noncompliance with audit committee requirements. The company had a cure period, generally until the earlier of its next annual meeting or November 8, 2018, and said it planned to fill the vacancy.
- Management identified risks including clinical and regulatory uncertainty, financing needs, competition, dependence on key personnel, and the ability to secure partnerships. It reported disclosure controls as effective and no material change in internal control during the quarter.
Most important facts for investors to verify
- Whether the reported $39.0 million cash balance and management’s runway estimate remain adequate against actual spending and planned trials.
- Next clinical and regulatory steps for Xilonix and the Phase II programs, including whether advanced studies proceed and their expected cost.
- Status and potential exposure of the securities litigation, including developments after the filing date.
- Whether XBiotech filled the audit committee vacancy and regained NASDAQ compliance within the stated cure period.
- Drivers and sustainability of reduced operating expenses, particularly given the smaller workforce and possible expansion of clinical programs.